IDEAYA Biosciences (IDYA)
(Real Time Quote from BATS)
$37.91 USD
-0.20 (-0.53%)
Updated Sep 4, 2024 09:44 AM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Cash flow Statements
Fiscal Year End for IDEAYA Biosciences, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -112.96 | -58.66 | -49.76 | -34.50 | -41.98 |
Depreciation/Amortization & Depletion | -9.08 | 1.41 | 3.56 | 1.96 | 0.77 |
Net Change from Assets/Liabilities | -11.68 | -41.56 | -17.81 | 84.41 | -0.28 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 18.49 | 11.63 | 8.24 | 3.59 | 2.17 |
Net Cash From Operating Activities | -115.22 | -87.18 | -55.78 | 55.46 | -39.31 |
Property & Equipment | -2.37 | -3.44 | -2.64 | -0.49 | -1.35 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -156.09 | -29.96 | -67.02 | -145.75 | 3.62 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -158.46 | -33.40 | -69.67 | -146.24 | 2.27 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 361.50 | 96.41 | 144.76 | 128.42 | 50.61 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 1.21 | 0.76 | 0.70 | 0.33 | 0.00 |
Net Cash from Financing Activities | 362.72 | 97.17 | 145.45 | 128.75 | 50.61 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 89.04 | -23.41 | 20.01 | 37.97 | 13.56 |
Cash at Beginning of Period | 68.74 | 92.15 | 72.14 | 34.17 | 20.61 |
Cash at End of Period | 157.78 | 68.74 | 92.15 | 72.14 | 34.17 |
Diluted Net EPS | -1.96 | -1.42 | -1.41 | -1.40 | -3.36 |
Fiscal Year End for IDEAYA Biosciences, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -92.34 | -39.57 | -112.96 | -79.01 | -51.57 |
Depreciation/Amortization & Depletion | -11.72 | -5.70 | -9.08 | -5.83 | -2.90 |
Net Change from Assets/Liabilities | 11.32 | -4.86 | -11.68 | -20.33 | -15.22 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 16.05 | 6.31 | 18.49 | 13.69 | 8.39 |
Net Cash From Operating Activities | -76.70 | -43.81 | -115.22 | -91.48 | -61.30 |
Property & Equipment | -2.30 | -1.33 | -2.37 | -1.53 | -0.93 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -283.12 | -352.65 | -156.09 | -44.98 | -96.93 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -285.41 | -353.97 | -158.46 | -46.51 | -97.86 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 387.51 | 349.11 | 361.50 | 221.19 | 193.35 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.78 | 0.00 | 1.21 | 0.64 | 0.64 |
Net Cash from Financing Activities | 388.29 | 349.11 | 362.72 | 221.82 | 193.99 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 26.19 | -48.67 | 89.04 | 83.83 | 34.83 |
Cash at Beginning of Period | 157.78 | 157.78 | 68.74 | 68.74 | 68.74 |
Cash at End of Period | 183.96 | 109.10 | 157.78 | 152.57 | 103.57 |
Diluted Net EPS | -0.68 | -0.53 | -0.51 | -0.46 | -0.50 |